Sigilon Therapeutics, Inc.

Sigilon Therapeutics, Inc. (SGTX) priced its initial public offering on Dec 7, 2020 at $18.00 per share, within its $17.00–$19.00 range, raising $126M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $543.4M. Ropes & Gray advised the company and Latham & Watkins advised the underwriters.

Sigilon Therapeutics, Inc. is a clinical-stage biotechnology company developing Shielded Living Therapeutics, engineered cells protected by biocompatible materials that continuously release missing therapeutic proteins, antibodies or hormones. Its lead candidate, SIG-001, is intended to prevent bleeding in patients with moderate-severe to severe Hemophilia A.

Status

IPO

Ticker

SGTX

Exchange

Nasdaq Global Select

Priced

Dec 7, 2020

IPO price

$18.00

Price range

$17.00–$19.00

Raised

$126M

Market cap at IPO price

$543.4M

First filed

Nov 13, 2020

Company counsel

Ropes & Gray

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.